Pacira Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on the stock and has a $38.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors tied to Pacira’s 2026 outlook and execution. He views the company’s revenue guidance for Exparel and total sales as both achievable and somewhat conservative, especially as management expects volume growth to translate more fully into revenue as discounting headwinds ease later in the year.
He also highlights that margins and operating expenses appear well controlled, with one-time 4Q costs not expected to repeat. In addition, he sees a meaningful growth catalyst from the NOPAIN Act and related reimbursement changes, which are already driving broader coverage, higher procedure volumes, and shifting prescribing behavior in favor of non-opioid options such as Exparel, reinforcing confidence in sustained demand and earnings power.
Tsao covers the Healthcare sector, focusing on stocks such as Argenx Se, Disc Medicine, and Praxis Precision Medicines. According to TipRanks, Tsao has an average return of 21.9% and a 53.41% success rate on recommended stocks.
In another report released today, TipRanks – PerPlexity also upgraded the stock to a Buy with a $26.00 price target.